The President Message for
International Seminar on Rare Blood Donor
Iranian Blood Transfusion Organization (IBTO)
Without blood and its components, saving lives of a large number of patients such as multiple transfused patients and persons with rare blood types would be impossible.
Transfusion Medicine has a long history in Iran. Since four decades ago and after the establishment of Iranian Blood Transfusion Organization (IBTO), all related activities including collection, quality control, surveillance and distribution of blood have been centralized and supervised by Ministry of Health (MOH).
During past four decades, IBTO has achieved remarkable successes that the greatest one, in recent years, was recording 100% voluntary non-remunerated blood donation in 2007.
Cultural and religious beliefs of Iranians not only led IBTO to the above goal and index of 27 donations per 1000 population, but also ranked Iran as pioneer nation in Eastern Mediterranean Region (EMR).
Collecting more than 2.1 million units of blood in 2013, applying an integrated quality assurance system and use of latest technologies in producing blood and blood products brought up IBTO as one of the prominent organization in Asia.
Through a suitable allocation of resources, Iranian health system has enabled IBTO to provide all patients with nationwide gratis products; hence, all patients are under umbrella of the service.
Due to risks related to blood transfusion and because the supply of blood and blood products is limited and costly, physicians should optimize blood usage and consider other alternatives to blood transfusion. We can reduce the need for blood transfusion by applying appropriate patient blood management, using autologous blood transfusion and trying to promote bloodless surgeries.
Since 2005, Iranian health system initiated a project to meet all Iranian needs for plasma-derived medicines based on donated plasma by Iranian donors; Although, the long term purpose of the program is to establish a national plasma fractionation center, main part of the needs of pharmaceutical market has been met by fractionation contracts with European partners. Regular audits by well-known international institutes are another verification fact to guarantee the quality of the products. Today, we are now able to produce 150,000 liters recovered and 100,000 liters source plasma.
Iranian health system covers all the hemophilia and thalassemia patients with free of charge medicines and treatments.
Establishment of Iranian National Rare Donor program is another successful example of the services mentioned.
Iran joined the ISBT Working Party on Rare Blood Donors in 2010. It is currently the only country from the Eastern Mediterranean Region in the Working Party.
To meet the requests of patients with rare blood groups, IBTO regularly screens rare blood types from blood donor samples. Today more than 20000 blood samples have been phenotyped serologically using manual and modern automated devices by Gel column and Magnetic technology and planning for complementary molecular testing and mass genotyping in the future.
Today I am honored that Iran is hosting an important seminar participated by international and national medical and laboratory experts working towards safer transfusion services.
I am extremely pleased to have had the opportunity to be a member of the huge family of IBTO